Alterity Therapeutics presents MSA program update at medical conferences
PUBT · 05/07 10:13
Share
Listen to the news
- Alterity Therapeutics scheduled to present Multiple System Atrophy data at ISMRM 2026 in Cape Town on May 12, 2026.
- Poster presentation at MDSANZ Scientific Meeting in Sydney set for May 15-17, 2026, covering results from a randomized, double-blind, placebo-controlled ATH434 study using CSF NfL as covariate.
- CEO David Stamler to give oral update on ATH434 clinical program and Phase 3 planning at MSA Symposium 2026 in London on May 18, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-015330), on May 07, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved